Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus

Exclusion Criteria

• - Have received chronic (>14 consecutive days) systemic adrenocorticosteroid therapy by oral, intravenous, or intramuscular route or intraarticular steroid injection within 4 weeks prior to study start.
• - Have been treated with drugs that promote weight loss within 90 days prior to study start.
• - Have been treated with drugs that directly affect gastrointestinal motility for > 21 consecutive days within 90 days prior to study start.
• - Have had prior exposure to exenatide BID or QW or participated in the clinical trial of exenatide BID or QW (including the case that the study drug was not administered).
• - Have been treated for >2 consecutive weeks with any of the following excluded medications within 90 days prior to study start: Insulin, Dipeptidyl peptidase-4 (DPP-4) inhibitors, GLP-1 analogs
• - Have received treatment within 30 days prior to study start drug that has not received regulatory approval for any indication.
• - Are currently enrolled in any other clinical study or participated in and completed the clinical study within 30 days prior to study start.
• - Have donated blood within 30 days prior to study start.